Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Partnership Overview - Absci Corporation and Owkin announced a strategic partnership to combine their AI platforms for the discovery and design of novel therapeutics [1] - The collaboration aims to accelerate the development of first-in-class therapeutics by leveraging Absci's AI de novo design models and Owkin's predictive AI target discovery technology [1][2] - The partnership will focus on co-developing therapeutic candidates in immuno-oncology, immunology, and inflammation [2] Technology and Capabilities - Owkin's predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids [2] - Absci's generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against novel targets [2] - The combined technologies aim to streamline and accelerate the path from research to clinical development [2] Strategic Impact - The partnership builds on Absci's growing portfolio of collaborations with industry leaders such as AstraZeneca and Merck [3] - Absci has added four new drug creation partnerships in 2024, achieving its outlook for the year [3] - Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies like Sanofi and BMS [3] Company Background - Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to accelerate the development of biologics [4] - The company's Integrated Drug Creation™ platform can screen billions of cells per week, enabling the transition from AI-designed antibodies to wet lab-validated candidates in as little as six weeks [4] - Owkin is an end-to-end AI biotech company focused on understanding complex biology and developing precision therapeutics, diagnostics, and de-risking clinical trials [5] - Owkin has raised over $300 million from leading biopharma companies and venture funds [5] Future Directions - The collaboration aims to bring transformative therapies to patients by combining Owkin's AI agents for target identification and validation with Absci's capabilities in developing biologic drug candidates [3] - The partnership represents a significant step forward in leveraging AI to accelerate the delivery of next-generation treatments [3]